Ante Jelaska
Author
Alternate names A. Jelaska, Ante Jelaska
Institution Boehringer Ingelheim (United States)
Past institutions Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany), Brampton Civic Hospital, Dallas Diabetes Research Center
H-index: 7
I10-index: 6
Works count: 10
Citations count: 885
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014 · Julio Rosenstock, Ante Jelaska, et al. · Diabetes Care
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015 · Julio Rosenstock, Ante Jelaska, et al. · Diabetes Obesity and Metabolism
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia
2013 · Julio Rosenstock, Leo Seman, et al. · Diabetes Obesity and Metabolism